Pular para o conteúdo principal
Ranking Invest

HRTX - Heron Therapeutics, Inc.

Segmento: HealthcareHeron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Análise Ranking Invest

Valuation estimado
-$ 184.33 Mi
Valor de Mercado
$ 59.90 Mi
Desconto (AV)-132.5%
IVR
-3.08A companhia vale -3,08 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-3.23O valuation alternativo equivale a -323% do valor de mercado da companhia.
MLL
-3.23O lucro líquido dos controladores em 16 trimestres equivale a -323% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 6.91 Mi

Dívida Líquida

-$ 20.72 Mi

L4T

-$ 34.05 Mi

MM4T

-22.75%

Indicadores Básicos

ROE

-492.89%

Índices de Previsibilidade

Receita Líquida

C0.05

Lucro

E1.86

Margem

E1.67

Índices de Tendência

Receita Líquida

B9.81

Lucro

A8.48

Margem

A8.83

Índices de Endividamento

DIV/PAT

-3.00

DIV/L4T

0.61

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.